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Autoinflammatory diseases are a group of disorders due to acquired or hereditary disfunction of innate immune
system and characterized by systemic or localized manifestations. The prototype is Familial Mediterranean Fever, a
monogenic hereditary disorder, whose causing gene (MeFV gene) was identified in 1997 and opened the way to a
new fascinanting chapter of rheumatology. A growing body of monogenic and poligenic autoinflammatory
disorders has been described since then.
Arterial and venous thrombosis is a common medical problem, with significant morbidity and mortality. Strong
evidences from basic research and clinical epidemiological studies support the theory that inflammation and
thrombosis can be associated.
Because of their recurrent/chronic inflammatory nature, autoinflammatory diseases are a putative cause of
thrombotic manifestations. In the present work, we reviewed the available evidences about monogenic
autoinflammatory disorders, complicated by thrombotic manifestations.
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Auto-inflammatory diseases (AIDs) are a group of
disorders, pathophysiologically characterized by ac-
quired or hereditary defects of innate immune system
and clinically by systemic and/or localized, chronic or
recurrent inflammatory manifestations. They are a quite
recent nosological group. The prototype is Familial
Mediterranean Fever, a monogenic hereditary disorder,
whose gene causing (MeFV gene) was identified in 1997
and opened the way to a new fascinanting chapter of
rheumatology. The discovery of this and other genes,
involved in autoinflammatory diseases, indeed, has
allowed not only to better understand the single disease,
but also the mechanisms of inflammation. The last clas-
sification of AIDs distinguishes between monogenic and
polygenic disorders. Monogenic diseases can be also
distinguished according to pathogenesis or their main
clinical features (Table 1) [1].
Thrombosis is a common medical problem, with sig-
nificant morbidity and mortality. Chronic inflammatory* Correspondence: micaela73@me.com
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unless otherwise stated.disorders are recognized risk factors for thrombotic dis-
eases, as inflammatory cytokines modulate the coagula-
tion pathway by enhancing procoagulants and inhibiting
anticoagulant and fibrinolytic systems. Further, endothe-
lial dysfunction, another component of the Virchow’s
triade leading to thrombosis, is associated with chronic
inflammation. Several epidemiological studies reported
increased morbidity and mortality from cardiovascular
diseases in patients with rheumatoid arthritis [2], and
strong evidences from basic research and epidemio-
logical studies support that inflammation and venous
thrombosis are associated processes [3].
Because of their recurrent/chronic inflammatory na-
ture, autoinflammatory diseases are a putative cause of
thrombotic manifestations. The aim of the present work
is to review available evidences about thrombosis and
monogenic autoinflammatory disorders. The association
with polygenic autoinflammatory disorders will be dealt
elsewhere in this issue.tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Classification of autoinflammatory diseases and their pathogenesis (modified from Ozen S, Nature Rev
Rheumatol 2014; 10:135–147)
Monogenic disease Pathogenesis
Periodic fever diseases
Familial Mediterranean fever, FMF Defects of IL-1Β family regulation
Hypepr IgD Syndrome, HIDS Defects of IL-1Β family regulation
TNF-receptor-associated periodic syndrome, TRAPS Protein mis-folding
Familial cold autoinflammatory syndrome 2, FCAS2 NFk-B activation
Cryopirin-associated periodic syndromes Defects of IL-1Β family regulation
Diseases with pyogenic lesions
Deficiency of IL-1 receptor antagonist, DIRA Defects of IL-1Β family regulation
Pyogenic arthritis, pyoderma gangrenosum and acne syndrome, PAPA Defects of IL-1Β family regulation
Majeed syndrome Defects of IL-1Β family regulation
Diseases with granulomatous lesions
Blau syndrome NFk-B activation
Diseases with psoriasis
Deficiency of IL-36 receptor antagonist Altered IL-36 regulation
Diseases with panniculitis-induced lipodistrophy
Joint contractures, muscle atrophy and panniculitis-induced lipodistrophy
syndrome, JMP
Disease linked to the proteasome and/or IFN-γ
Chronic atypical neutrophilic dermatosis with lipodistrophy and elevated
temperature, CANDLE
Disease linked to the proteasome and/or IFN-γ
Nakajo-Nishimura syndrome, NNS Disease linked to the proteasome and/or IFN-γ
Others
PLCγ2-associated antibody deficiency and immune dysregulation
syndrome, APLAID
Alteration of inflammation signalling and immune response
Poligenic diseases
Gout IL-1B activation
Schnitzler syndrome IL-1B activation
Behçet disease Spontaneous and/or induced overexpression of pro-inflammatory Th1
type cytokines – HLA-B51
Systemic-onset juvenile idiopathic arthritis (JIA) IL-1B activation
Crohn’s disease Altered innate and adaptive immune system (Th1 and Th17 mediated
process)
Aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome Altered innate and adaptive immune system (IL-1B–18 activation and Th1
chemokines induction)
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Search strategy
We performed a systematic review of studies reporting
arterial and venous thrombosis in patients with autoinflam-
matory diseases. Studies had to have published in peer-
reviewed journals.
We searched Medline/PubMed using terms: (((“Throm-
bosis” [Mesh] OR ((“Superior Vena Cava Syndrome”
[Mesh]) OR ((“Infarction, Middle Cerebral Artery” [Mesh])
OR ((“Budd-Chiari Syndrome” [Mesh]) OR ((“Retinal Vein
Occlusion” [Mesh]) OR ((“Carotid Artery Thrombosis”
[Mesh]) OR ((“Intracranial embolism and thrombosis”
[Mesh]) OR ((“Coronary Thrombosis” [Mesh]) OR ((“SinusThrombosis, Intracranial” [Mesh]) OR ((“Embolism and
Thrombosis” [Mesh]) OR ((“Sagittal Sinus Thrombosis”
[Mesh]) OR ((“Cavernous Sinus Thrombosis” [Mesh]) OR
((“Lateral Sinus Thrombosis” [Mesh]) OR ((“Venous
Thrombosis” [Mesh]) OR ((“Intracranial Thrombosis”
[Mesh]) OR ((“Upper Extremities Deep vein Thrombosis”
[Mesh]) OR ((“Stroke”) OR ((“Myocardial Infarction”) OR
((“Deep vein thrombosis”) AND ((“Hereditary Autoinflam-
matory Disorders” [Mesh]) retrieving 41 articles. Eighteen
were eligible for the review. Then, we used the same search
terms AND ((“Familial Mediterranean Fever”), retrieving
33 papers, 22 elegible; AND ((“Periodic fever, familial,
autosomal dominant” [Supplementary Concept] [Mesh])
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Fields] [Mesh]), AND ((“Cryopyrin-Associated Periodic
Syndromes”) AND ((“Familial Cold Autoinflammatory
Syndrome 2” [Supplementary Concept]) AND ((“Inflam-
masomes”) AND ((“NLRP3 protein, human” [Supple-
mentary Concept] [Mesh]) AND ((“Pyogenic arthritis,
pyoderma gangrenosum and acne syndrome”) AND ((“De-
ficiency of IL-36 receptor antagonist”) AND ((“Joint
contractures, muscle atrophy and panniculitis-induced
lipodistrophy syndrome”) AND ((“Chronic atypicalTable 2 List of case reports and case series about thrombotic
Authors Type of
publication
Thrombotic manifestation
Joo K et al. Case report total thrombosis of splenic vein with partial
thrombosis of proximal superior mesenteric v
main portal vein and intrahepatic both porta
Ambartsymian
SV
Autoptic
case series
(68 patients)
amyloid angiopathias, with narrowing or
obstructing of arterioles and coronary vasculi
Luger S et al. Case report Brain stem infarction due to CNS vasculitis
Feld O et al. Review and
case-series
(11 patients)
Stroke/TIA
Unal F et al. Case series
(2 patients)
Budd-Chiari syndrome
Korkmaz C
et al.
Review and
case series
(2 patients)
1. Left cerebral infarct 2. Suspected mesenter
ischemia
Ruiz XD et al. Case report Pulmonary embolism
Standing AS
et al.
Case report Budd-Chiari syndrome
Kalyonku U
et al.
Case series
(7 patients)
Cerebrovascular accident
Sari S et al. Case series
(2 patients)
Budd-Chiari syndrome
Aoun G et al. Case report Stroke (right lateral medullary syndrome)
Uyarel U et al. Case report Acute myocardial infarction
Serrano R et al. Case report Acute myocardial infarction due to coronary
vasculitis
Ustundag Y
et al.
Case report Superior vena cava thrombosis
Finsterer J
et al.
Case report CNS and PNS vasculitis or amyloidosis
Reuben A
et al.
Case series
(7 patients)
Renal vein thrombosis
Puricel S et al. Case series
(1 patient)
Acute coronary syndrome
Lidar M et al. Case series
(6 patients)
Thrombo-embolismneutrophilic dermatosis with lipodistrophy and elevated
temperature”) AND ((“PLCγ2-associated antibody defi-
ciency and immune dysregulation syndrome”) AND
((“NakaJo-Nishimura syndrome”) with no items found;
AND ((“Deficiency of IL-1 receptor antagonist”) AND
((“Majeed syndrome”) with 7 items found, no one elegible
for our review; AND ((“Muckle-Wells”) with 2 items
found, one eligible for our review.
Eligibility criteria were: studies reporting cases of
autoinflammatory syndromes complicated by arterialmanifestations in FMF patients
Other thrombosis risk factors Genetically proven FMF
ein,
l vein
Decreased protein S activity 3 mutations
(p.Glu148Gln,p.Pro369Ser,
p.Arg408Gln)
tis
Data not available Data not available
Data not available Yes
renal amyloidosis and
haemodialysis, and three had
smoking, hypertension, diabetes
mellitus and obesity
Data not available
Data not available Yes
ic Amyloidosis, anticardiolipin
antibodies Pregnancy
Yes Homozigosity for
M694V Data not available
Data not available Heterozygous M649V
Heterozygous for MTHFR mutation Homozygous E148Q
In 3 patients: significant patent
foramen ovale, thalassaemia major
and carotid artery dissection
Yes All homozygosis for
MEFV mutations (6/7
homozygosis for M694V)
FV Leiden single mutation
Homozygosity for MTHFR mutation
Yes Homozygosity for
M694V
Lupus anticoagulant FV leiden and
MTHFR heterozygous mutations
Yes Homozygosity for
M694V
No known coronary risk factors Data not available
Amyloidosis Chronic renal failure on
hemodyalisis Cyclosporin
Data not available
Obesity Not available
Data not available Yes Homozygosity for
M694V
Amyloidosis Data not available
Data not available Data not available
Data not available Data not available
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gating coagulation in autoinflammatory syndromes or
autoinflammatory genes mutations in patients with
cardiovascular diseases.Results
Our research retrieved 33 papers about familial
Mediterranean fever (FMF) complicated by thrombotic
diseases (22 after exclusion of duplicated papers), 2 about
TNF receptor associated periodic syndrome (TRAPS) and
increased risk of atherosclerosis and acute myocardial
infarction and one about Muckle-Wells syndrome
(MWS)/neonatal-onset multisystem inflammatory dis-
ease (NOMID) overlap complicated by cerebrovascular
accident (CVA).
This latter reports the case of a woman with overlap-
ping manifestation of MWS and NOMID that experi-
enced a cerebrovascular attack (leftsided weakness,
vertigo and paresthesia; altered brain CT scan) at the age
of 28. The authors do not mention other traditional risk
factors for thrombotic diseases; anyway, they specify they
did not search for anticardiolipin antibodies.
The association of FMF with thrombotic manifesta-
tions, instead, relies on 4 laboratory studies, 2 review, 9
case reports and 9 case series, ranging from pulmonary
embolism to thrombosis in atypical sites, stroke or myo-
cardial infarction. Details are shown in Table 2.
A series of patients with premature myocardial infarc-
tion and a series of patients with symptoms suggestive
of TRAPS support the relationship between atheroscler-
osis and TNFR-1 mutations.Familial mediterranean fever and stroke
The occurrence of cerebral stroke in FMF patients is lim-
ited to three cases and two retrospective studies [4-8].
One case report is about a child, who in addition to
FMF had several prothrombotic defects [4], the second
about a 21 year-old man with nephrotic syndrome com-
plicated by AA amyloidosis, and lupus anticoagulant in
low titre [5], the third about a young patient who suf-
fered of a brain stem infarction during a typical FMF at-
tack [6]. All of them have genetically proven FMF.
The retrospective study by Kalyoncu et al. [7] identi-
fied seven cases of stroke among 3034 FMF patients.
They were younger (mean age 28.5 years) compared to
patients with stroke but not FMF, and vertebrobasilar
vessels were the most affected. All the patients were
homozygous for the MEFV mutations (M694V in six pa-
tients), but they started colchicine late, so they were ex-
posed to long-lasting inflammation. Three of them had
also established risk factors for stroke, such as haemo-
dynamically significant patent foramen ovale, thalassae-
mia major and carotid artery dissection.The second retrospective study by Feld et al. [8] re-
ported a diagnosis of stroke/transient ischaemic attack
(TIA) in 11 FMF patients younger than 50 years, admit-
ted to Sheba Medical Center from 1985 to 2010. Also in
this series, other risk factors prevailed: two patients had
renal amyloidosis and were on haemodialysis, and three
had at least one traditional risk factor such as smoking,
hypertension, diabetes mellitus and obesity.
Being FMF characterized by massive inflammation, ei-
ther during attacks and free intervals, FMF patients
should display an increased rate of atherosclerotic vascu-
lar disease, including cerebral stroke. Some studies, in-
deed, reported an increased intima-media thickness of
the carotid artery and other markers of enhanced ath-
erosclerosis in FMF [9-13]. Not to forget also amyloid-
osis - the most dangerous FMF-complication, which is
characterized by a thrombophilic profile, with an in-
creased frequency of venous and arterial thrombosis -
and vasculitis, another process responsible for stroke in
FMF patients. Henoch-Shoenlein Purpura (HSP), Polyar-
teritis nodosa (PAN) and Behcet’s disease (BD), common
vasculites in FMF, can affect central nervous system
[14,15]: BD more than HSP more than PAN [16-19].
Sinus vein thrombosis, stroke, multifocal neurologic dys-
functions of cranial nerves and retinal vessel occlusion
have been described in patients with BD and FMF [20].
Familial Mediterranean fever and myocardial infarction
We found 2 case reports of myocardial infarction occur-
ring in patients with FMF [21,22]. A third case is in-
cluded in a study on aetiology of acute corornary
syndrome under the age of 30 [23]. The patient reported
by Urayel et al. is a 22-year-old man who developed a
fatal myocardial infarction after stopping colchicine [21].
The other one by Serrano et al. is a 29-year-old Spanish
woman with a history of FMF, AA amyloidosis and pre-
vious renal transplantation who experienced a fatal acute
myocardial infarction, due to coronary vasculitis with
hystopathologic features different from PAN [22].
The review by Rigante et al. about cardiovascular man-
ifestations in autoinflammatory diseases [24] cites the
work by Grimaldi et al. where a MEFV mutation
(M694V) was significantly overrepresented in a cohort
of infarcted patients from Sicily than in age-matched
healthy controls and continued to predict a significant
risk to develop MI, even after adjustment for well-
known MI risk factors [25].
At the end, there is an autoptic study including sixty-
eight patients with FMF and cardiac lesions that shed
light on the mechanisms responsible for myocardial in-
farction in FMF population. The author described amyloid
angiopathias, which were more expressed in arteriolar
walls, with narrowing or obstruction of lumina, associated
with coronary vasculitis. Other predisposing pathogenic
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plicated by amyloid depositions in the vessels walls [26].
Familial mediterranean fever and venous thrombosis in
typical and atypical site
No cases of lower or upper extremities deep vein throm-
bosis in patients with FMF are described in literature.
There is just the case of a 43-year-old Turkish man with
FMF presenting with pulmonary embolism [27] and a
case series of 6 patients with FMF and amyloidosis who
died due to thromboembolic phoenomena (one massive
pulmonary embolism) [28].
Among atypical sites, splancnic district appears the
most affected. We found 4 case reports of Budd-Chiari
syndrome [29-31] and 1 case of portal, splenic and su-
perior mesenteric vein thrombosis [32] occurring in pa-
tients affected by FMF. There is also another case where
a mesenteric thrombosis was suspected but it can not be
ascertained because the relatives refused autopsy [5].
Superior vena cava thrombosis complicating FMF was
described in a woman who developed also obstructive
sleep apnea because of thrombosis-induced soft tissue
edema in the upper airways [33].
Renal vein thrombosis, instead, was described in 7 of
57 FMF patients with nephrotic syndrome, histologically
proven amyloidosis, and progressive renal failure [34].
Laboratory studies
Our search identified also four studies and one review
investigating coagulation parameters in FMF patients.
Aksu et al. demonstrated the presence of a hypercoag-
ulable state in 27 attack-free FMF patients without amyl-
oidosis [35]. They found shortened TT and prothrombin
time, decreased protein C activity and increased levels of
human prothrombin fragment F 1 + 2 in FMF patients
compared to healthy controls, in absence of other pre-
disposing factors for thrombosis.
Demirel et al. investigated thrombotic and fibrinolytic
markers in 64 FMF patients during and outsides attacks
and in healthy controls [36]. They found a prolongation
of PT during attacks, increased levels of PAI-1, inhibitor
of fibrinolysis and maker of endotelial dysfunction com-
pared to attack-free patients and healthy controls, but
also increased levels of tissue plasminogen activator
(tPA), trigger of the fibrinolytic system, and decreased
levels of P-selectin, marker of thrombocyte activation,
during the attack period compared to healthy controls.
The levels of tPA were found high also in the attack-free
period compared to the control group, but the difference
was not statistically significat. vW factor and F VIII
levels were comparable with those of the controls. At
the end the authors hypothesize that hypercoagulability
may have a role in the etiopathogenesis of FMF and
PAI-1 could be used as a marker of the attacks.Ertenli et al. studied fibronectin (FN) and thrombos-
pondin (TSP) that just play a role in coagulation and in-
flammation. Plasma fibronectin and thrombospondin
levels during FMF attack periods resulted significantly
higher than after attacks resolution. A significant correl-
ation between both FN, TSP and CRP levels and WBC
counts was also reported [37].
Gasparyan et al. reviewed the evidences about the use
of mean platelet volume (MPV), a parameter readily
available from blood counters, as reflection of prothrom-
botic and pro-inflammatory situations [38]. He found
that FMF attacks are associated with a decrease of MPV
in pediatric patients [39], probably due to the consump-
tion of large platelets at the sites of serositis. In attack-
free adult FMF patients, instead, circulating platelets
tend to be larger and it may be considered as a marker
of cardiovascular risk [40].
At the end, Bavbek N et al. [41] demonstrated a high
level of Thrombin-activatable fibrinolysis inhibitor
(TAFI) antigen in attack-free period of FMF disease, sup-
porting the idea of hypercoagulability.
Tumor necrosis factor receptor and associated periodic
syndrome (TRAPS) and myocardial infarction
Polymorphism R92Q of the tumor necrosis factor recep-
tor 1 (TNFR-1) gene has been associated with myocar-
dial infarction (MI) in a cohort of 95 individuals with
premature myocardial infarction and familiarity for MI.
The population-adjusted odds ratio (OR) for MI associ-
ated with allele Q carrying was 2.15 (95% CI: 1.09-4.23).
To search for its responsibility in atherosclerosis, this
polymorphism was also genotyped in the AXA Study
(ultrasound examinations of carotid and femoral arteries
in the context of an employment medical examination,
733 subjects), the EVA Study (ultrasound examinations
of carotid arteries in a study of cognitive and vascular
ageing, 1092 subjects) and the GENIC Study [on brain
infarction (BI), 912 subjects]. In the AXA Study, a posi-
tive association with a carotid plaque was found among
smokers, carrying the 92Q allele (OR 5.07; 95% CI: 1.64-
15.63) and with a thickening of the carotid intima-media
thickness (IMT) (0.59 (0.11) vs 0.54 (0.11), P = 0.045). In
the EVA Study, carriers of allele 92Q had an increased
mean carotid IMT 0.70 (0.09) vs 0.67 (0.13), P = 0.02).
No significant association of the 92Q allele was found
with BI in the GENIC Study [42]. Some years later
Stojanov S et al. postulated that the TNFRSF1A V173D
cleavage site mutation may be associated with an
increased risk for cardiovascular complications and
showed a strong response to etanercept [43].
The link between TRAPS and atherosclerosis can be
mediated also by adipokines, as it has been demon-
strated on one hand, that serum leptin significantly cor-
relates with markers of subclinical atherosclerosis [44]
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cular disease [45] and, on the other hand, preliminary
research showed a correlation between serum leptin and
adiponektin and disease activity and/or severity [46].
Discussion
Inflammation is the physiologic response of the body to
various insults. Generally, it is self-limited and specific
to injury. Sometimes the inflammatory response is in-
appropriate in terms of triggers (self, inapparent or
otherwise innocuous), intensity or duration. Excessive
inflammation due to hereditary defects in inflammatory
cells occurs in the autoinflammatory disorders, topic of
the present review.
Similarly, haemostasis is the normal response of ves-
sels to injury by forming a clot that serves to limit haem-
orrhage. Thrombosis, instead, is a pathological clot
formation that results when hemostasis is excessively ac-
tivated in absence of bleeding.
Inflammation and coagulation are intricated processes
that show crosstalk at numerous levels. Inflammation in-
duces and/or enhances thrombosis and viceversa.
If we look at the inflammatory pathway of hereditary
autoinflammatory diseases, it just displays some crosstalk
between inflammation and coagulation. Mutated pyrin and
cryopyrin, isoprenoids and their products and mutated
TNFR1 enhance intracellular enzymes such caspases, tran-
scriptional factors such as NFkB and cytokines like IL-1B,
known to increase the release of tissue plasminogen activa-
tor (tPA) and urokinase-type plasminogen activator (uPA)
from the storage sites in vascular endothelial cells, a sus-
tained and late release of PAI-1 and downregulate throm-
bomodulin and subsequently the activation of protein C, a
natural anticoagulant. Neverthless, autoinflammation can
lead to thrombosis, via endothelial injury and endothelial
cell dysfunction (ECD), by the activation of platelets, leuko-
cytes and endothelial cells or via Tissue factor (TF) overex-
pression, in absence of vessel wall damage [47].
On the other hand, coagulation can modulate inflam-
mation, as
– thrombin and some other coagulation factors may
bind to protease-activated receptors (PAR) on endo-
thelial and mononuclear cells, fibroblasts, platelets
and smooth muscle cells with subsequent produc-
tion of growth factors and cytokines including IL-6
and IL-8 [48]
– thrombin may induce endothelium to express P-
selectin and to secrete palsminogen activating factor
(PAF) and work as a chemotactic factor for leuko-
cytes [49,50]
– fibrinogen and fibrin can directly stimulate
mononuclear cells to secrete proinflammatory
molecules, such as TNF-, IL-1, and MCP-1 [50]– platelets can activate dendritic cells through which
they may regulate T- and B- cell responses, and along
with platelet microparticles, activate complement
cascade [51]
– platelet derived chemokines can play important roles
in innate immunity [52,53].
With these assumptions, we would have expected
much more cases of thrombosis in patients affected by
autoinflammatory diseases than we found, and not only
in patients affected by familial mediterranean fever.
Here, we would try to give some explanations.
First of all, hereditary autoinflammatory diseases
(HAID) are rare diseases, so the small prevalence of
thrombosis could be only apparent. In fact, the seven cases
of stroke out of 3034 patients in the series reported by
Kalyoncu et al. [54] correspond to a prevalence higher
than general population (0.2 vs. 0.005–0.01% for adults
<50 year old). The same is for the Budd-Chiari syndrome
whose prevalence ranges from 1.4-2.4/million inhabitants
and we found 4 cases complicating FMF that affects ap-
proximately 100.000-150.000 individuals worlwide [55].
Second, autoinflammatory diseases other than FMF
are much rarer, so the lack of case reports can not ex-
clude the existence of complicating thromboses.
Third, the duration of inflammation can play a role in
the prevalence of thrombosis in the different autoinflam-
matory disorders. In this view, an autoinflammatory dis-
ease, like FMF, characterized by intermittent and short-
lasting inflammatory attacks could be less frequently
complicated by thrombosis, while the persisting inflam-
mation of Behcet’s disease, can justify its high frequency
of thrombotic complications. Just considering fibrinogen
kinectics, short-lasting inflammation is less likely to de-
termine thrombosis [56]. In this view, FMF patients with
more severe mutations, such as M694V, associated with
a higher frequency of attacks could experience throm-
bosis more often. Furthermore, a direct mutation effect
can not be excluded, as more than one study has dem-
onstrated that M694V is associated to vascular involve-
ment in Behcet’s diseases [20,57], even if not in all the
ethnic groups [58,59]. So, the high prevalence of M69V
mutation in the reported cases of FMF complicated by
thrombosis could not be a chance.
Fourth, the reported cases are all symptomatic. We miss
data about asymptomatic thrombosis complicating HAIDs
to support autoinflammation as a cause of thrombosis.
Lastly, basic studies reported an activation of both co-
agulation and fibrinolysis in FMF patients, suggesting a
sort of balance between the two processes during and
out of the attacks and clinical studies disclosed the pres-
ence of additional thrombotic risk factors, first of all sec-
ondary amyloidosis, in all the patients, but one. So, it is
conceivable that additional thrombotic risk factors are
La Regina et al. Thrombosis Journal  (2015) 13:19 Page 7 of 8necessary to break this balance between inflammation-
induced coagulation and fibrinolysis and develop throm-
bosis in FMF patients. A recent cross-sectional study
has shown an increased risk of cardiovascular disease in
Turkish FMF patients with nephrotic-range proteinuria
and amyloidosis compared with patients with nondia-
betic glomerulopathy [60].
Another important issue to be addressed is the role of
colchicine treatment in preventing thrombosis. By sup-
pressing inflammation and preventing amyloid deposis-
tion, colchicine offers at least two ways to avoid
thrombotic complications. Indeed, most of the patients
in the case reports developed thrombotic complications
before starting or after stopping colchicine. A retrospect-
ive investigation about the prevalence of ischemic heart
disease and cardiovascular risk factors in FMF has
shown that colchicine therapy ameliorates cardiovascular
risk profile and makes FMF patients comparable to
healthy controls [61]. Similarly, some case–control stud-
ies including FMF patients on colchicine therapy did not
display significant differences in terms of subclinical ath-
erosclerosis between FMF patients and healthy subjects
[62]. The ongoing Canakinumab Anti-inflammatory
Thrombosis Outcomes Study (CANTOS) is just testing
whether reducing inflammation among men and women
who have had a prior heart attack and have CRP > 2
ngm/ml can reduce the risk of another cardiovascular
event happening in the future. If positive, CANTOS will
provide the first cytokine-based therapy for the second-
ary prevention of cardiovascular disease and new-onset
diabetes [63].Conclusions
If autoinflammatory diseases are a possible cause of
thrombosis is still to be stated.
At present, a higher prevalence of thrombotic manifes-
tations compared to general population and a concomi-
tant activation of inflammation and coagulation cascade
have been demonstrated in FMF patients.
In the next future, the existing international registries,
including patients with any of the HAIDs, could try
to address the issue of prevalence. Large randomized
controlled studies, instead, could clarify the role of
colchicine/anti-TNF/anti-IL-1B treatment or assess the
responsibility of particular mutations. Once the throm-
botic face of autoinflammatory diseases will be displayed,
the need of thromboprophylaxis during attack periods or
the screening for thrombophilia in HAIDs patients will
be emerging issues.
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